[PET and PET/CT in relapsing prostate carcinoma].
Of patients with carcinoma of the prostate undergoing therapeutic regimes with curative intent, 15-23% will ultimately relapse and 16-35% will need some sort of salvage therapy within 5 years. Of relapsing patients, 50% will have local recurrence and 50% systemic disease with or without local recurrence. Therefore, localization of recurrent prostate cancer is critical for selecting a local or systemic therapeutic strategy. Modern fusion imaging with PET/CT and 11C/18F-choline or 11C-acetate has augmented the diagnostic imaging spectrum for assessment of relapsing prostate cancer. In 60-70% of patients with biochemical relapse, recurrent tumor can be detected and anatomically precisely localized. Detection sensitivity is probably negatively correlated with serum PSA concentration. Below a PSA level of 1 ng/ml, mean detection sensitivity is probably 50-66%. Fusion imaging with 11C-choline PET/CT and MRI possesses a high potential for early localization of recurrent prostate carcinoma.
Reske
S N
SN
Klinik für Nuklearmedizin, Universitätsklinikum, Robert-Koch-Strasse 8, 89081, Ulm, Germany. sven.reske@uniklinik-ulm.de
Blumstein
N M
NM
Glatting
G
G
D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000517:prevention & control; D049268:Positron-Emission Tomography / Q000379:methods*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013382:Subtraction Technique; D014057:Tomography, X-Ray Computed / Q000379:methods*